Chemical Engineering @ChemengFiles.Com

Braskem and Acinplas just a close partnership for the provision of green polyethylene from 100% renewable origin. The resin is used in the manufacture of plastic films, which will be transformed into a licensed product under the name Unisold System ®, used by companies run by Acinplas - Suzuki, Koba, Plasa, and Tashiro Voti & Takata. This system helps the consumer in the purchase of fruit and vegetable sector frutihortícola of the major supermarkets in Brazil and Europe, providing perforated bags to put up with convenience foods, health and strength.

The partnership was made possible thanks to the goal of sustainable business practices, particularly with regard to the environment because the consumer market increasingly demands products produced by environmentally correct and socially and environmentally responsible.

Braskem and Acinplas just a close partnership for the provision of green polyethylene from 100% renewable origin. The resin is used in the manufacture of plastic films, which will be transformed into a licensed product under the name Unisold System ®, used by companies run by Acinplas - Suzuki, Koba, Plasa, and Tashiro Voti & Takata. This system helps the consumer in the purchase of fruit and vegetable sector frutihortícola of the major supermarkets in Brazil and Europe, providing perforated bags to put up with convenience foods, health and strength.

The partnership was made possible thanks to the goal of sustainable business practices, particularly with regard to the environment because the consumer market increasingly demands products produced by environmentally correct and socially and environmentally responsible.

Companies International Petroleum Investment Company (IPIC) and NOVA Chemicals Corporation announced the completion of acquisition of NOVA Chemicals through a funding agreement ( "Agreement"). NOVA Chemicals will continue to operate segments of chemicals and plastics from its base in United States.

"We are very happy to end this transaction and are excited about the future opportunities that NOVA Chemicals will have to grow in Alberta and elsewhere," said Chris Pappas, President and CEO of NOVA Chemicals. "Our team is focused on leveraging renewed financial strength to bring our industry-leading technology from our operational base in Canada to the world. "

Companies International Petroleum Investment Company (IPIC) and NOVA Chemicals Corporation announced the completion of acquisition of NOVA Chemicals through a funding agreement ( "Agreement"). NOVA Chemicals will continue to operate segments of chemicals and plastics from its base in United States.

"We are very happy to end this transaction and are excited about the future opportunities that NOVA Chemicals will have to grow in Alberta and elsewhere," said Chris Pappas, President and CEO of NOVA Chemicals. "Our team is focused on leveraging renewed financial strength to bring our industry-leading technology from our operational base in Canada to the world. "

Seambiotic has announced that its subsidiary in the U.S., Seambiotic USA has entered into an agreement with NASA Glenn Research Center to develop a program of collaborative R & D for optimization of processes of growth of microalgae open pond.

Seambiotic has announced that its subsidiary in the U.S., Seambiotic USA has entered into an agreement with NASA Glenn Research Center to develop a program of collaborative R & D for optimization of processes of growth of microalgae open pond.

Helsinn has announced new plans to create a competitive organization focused on manufacturing highly potent compounds with a remarkable capacity for R & D and production. Both investments and manufacturing facilities of the new organization of Ireland and Switzerland are part of this strategy.

In March this year, Helsinn made an investment of around EUR 13 million, receiving support from the Government of Ireland through the IDA (Irish Development Authority) to build a center of excellence in the field of research and development of oral solid dosage (OSD), creating 10 positions for high-value research in one of its facilities near Dublin (Ireland). Now, Helsinn Chemicals in Biasca Organization (Switzerland), after an initial investment of 5 million euros completed in recent years, aims to expand its services in developing and manufacturing facilities in Switzerland Helsinn Advanced Synthesis.

Helsinn has announced new plans to create a competitive organization focused on manufacturing highly potent compounds with a remarkable capacity for R & D and production. Both investments and manufacturing facilities of the new organization of Ireland and Switzerland are part of this strategy.

In March this year, Helsinn made an investment of around EUR 13 million, receiving support from the Government of Ireland through the IDA (Irish Development Authority) to build a center of excellence in the field of research and development of oral solid dosage (OSD), creating 10 positions for high-value research in one of its facilities near Dublin (Ireland). Now, Helsinn Chemicals in Biasca Organization (Switzerland), after an initial investment of 5 million euros completed in recent years, aims to expand its services in developing and manufacturing facilities in Switzerland Helsinn Advanced Synthesis.

AMRI has announced that it has completed construction of a new facility for chemical R & D in Budapest (Hungary). The completion and transfer to the 3,000 square feet of laboratory and administrative space represents an important milestone in the business plan initiated in 2008 to transform its central European business services discovery of higher value through the consolidation of several locations equipment and operating costs.

In addition to significant improvements in operational efficiencies and improved technology transfer, the new site provides capacity for the planned expansion of the synthetic chemistry, which currently is expected to double over the next five years.

AMRI has announced that it has completed construction of a new facility for chemical R & D in Budapest (Hungary). The completion and transfer to the 3,000 square feet of laboratory and administrative space represents an important milestone in the business plan initiated in 2008 to transform its central European business services discovery of higher value through the consolidation of several locations equipment and operating costs.

In addition to significant improvements in operational efficiencies and improved technology transfer, the new site provides capacity for the planned expansion of the synthetic chemistry, which currently is expected to double over the next five years.

Tauw has been contracted by the World Bank to advise it on how to deal with old pesticides and organic pollutants that are difficult to decompose (POP) in Kyrgyzstan, Tajikistan and Uzbekistan. Tauw consultants will be engaged in knowledge transfer for the delineation of an inventory and how to treat the former storage space of these toxic substances.

In each of the three countries, ten people will be trained to locate and make an inventory of former storage space. Moreover, inspecting a landfill site in each country more closely, after which they will design a technical sanitation.

Tauw has been contracted by the World Bank to advise it on how to deal with old pesticides and organic pollutants that are difficult to decompose (POP) in Kyrgyzstan, Tajikistan and Uzbekistan. Tauw consultants will be engaged in knowledge transfer for the delineation of an inventory and how to treat the former storage space of these toxic substances.

In each of the three countries, ten people will be trained to locate and make an inventory of former storage space. Moreover, inspecting a landfill site in each country more closely, after which they will design a technical sanitation.

A new and crucial collaboration between Global Alliance for TB Drug Development (TB Alliance) and Tibotec Inc. was announced at the Pacific Health Summit, in response to the urgent need to accelerate the discovery and development new drugs to combat tuberculosis (TB).

The two organizations will share their knowledge and resources in the development of TMC207, which could become the first drug for tuberculosis with a new mechanism of action in 40 years. Provisional data from a Phase II study of TMC207 in progress were published recently in The New England Journal of Medicine. In placebo-controlled study of 47 patients with multidrug-resistant tuberculosis (MDR-TB for short), it was noted that 48 percent of patients who received TMC207 in combination with standard treatment were negative sputum cultures after eight weeks compared with 9 percent of those receiving a placebo and standard treatment.

A new and crucial collaboration between Global Alliance for TB Drug Development (TB Alliance) and Tibotec Inc. was announced at the Pacific Health Summit, in response to the urgent need to accelerate the discovery and development new drugs to combat tuberculosis (TB).

The two organizations will share their knowledge and resources in the development of TMC207, which could become the first drug for tuberculosis with a new mechanism of action in 40 years. Provisional data from a Phase II study of TMC207 in progress were published recently in The New England Journal of Medicine. In placebo-controlled study of 47 patients with multidrug-resistant tuberculosis (MDR-TB for short), it was noted that 48 percent of patients who received TMC207 in combination with standard treatment were negative sputum cultures after eight weeks compared with 9 percent of those receiving a placebo and standard treatment.

The top management of Helsinn Healthcare announced that it has signed a partnership agreement with Zealand Pharma, for the development and global marketing of ZP1846, a GLP-2 receptor agonist (glucagon-like peptide of type 2) provides that a new way to treat chemotherapy-induced diarrhea (CID), a debilitating condition that effects patients undergoing cancer treatment with a series of chemotherapy.

The top management of Helsinn Healthcare announced that it has signed a partnership agreement with Zealand Pharma, for the development and global marketing of ZP1846, a GLP-2 receptor agonist (glucagon-like peptide of type 2) provides that a new way to treat chemotherapy-induced diarrhea (CID), a debilitating condition that effects patients undergoing cancer treatment with a series of chemotherapy.

Rohm and Haas Company, a leading producer of special materials, currently focus for the investments being made in Turkey, will participate in Plast Eurasia 2008 in Istanbul later this week. Last October, Rohm and Haas opened a facility acrylic impact modifiers and production assistants in northwestern Turkey, in the town of Gebze.

Rohm and Haas Company, a leading producer of special materials, currently focus for the investments being made in Turkey, will participate in Plast Eurasia 2008 in Istanbul later this week. Last October, Rohm and Haas opened a facility acrylic impact modifiers and production assistants in northwestern Turkey, in the town of Gebze.

The global financial crisis will be a key topic of discussion during the meeting of industry leaders in the Third Annual Forum of GPCA (Gulf Petrochemicals & Chemicals Association), organized by the GPCA, in conjunction with Chemical Week , From 2 to 4 December 2008 in Atlantis, The Palm, Dubai, United Arab Emirates.

The global financial crisis will be a key topic of discussion during the meeting of industry leaders in the Third Annual Forum of GPCA (Gulf Petrochemicals & Chemicals Association), organized by the GPCA, in conjunction with Chemical Week , From 2 to 4 December 2008 in Atlantis, The Palm, Dubai, United Arab Emirates.